Pyruvate Kinase Activator Drug Class List

Drugs in Drug Class: Pyruvate Kinase Activator

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No	11,878,049
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No	10,632,114
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No	11,254,652		Y	Y

Market Dynamics and Patent Landscape for Pyruvate Kinase Activators

Last updated: January 7, 2026

Summary

Pyruvate Kinase (PK) activators constitute an emerging class of metabolic modifiers primarily targeting disorders like pyruvate kinase deficiency (PKD), a rare hereditary hemolytic anemia, and potential applications in oncology and metabolic diseases. This report examines the current market landscape, including key players, patent protections, and potential growth trajectories. It analyzes regulatory pathways, competitive dynamics, innovation trends, and patent expirations influencing the evolution of PK activator drugs. Deep insights into market drivers, barriers, and the patent landscape aim to equip stakeholders for informed strategic decision-making.

---

What Are Pyruvate Kinase Activators?

Pyruvate Kinase (PK) is a critical enzyme in glycolysis, catalyzing the conversion of phosphoenolpyruvate (PEP) to pyruvate, generating ATP. PK activators enhance enzyme activity, especially targeting PKR isoform (pyruvate kinase ribosomal), implicated in red blood cell metabolism.

Role in Disease Therapy

• Pyruvate Kinase Deficiency (PKD): A rare, autosomal recessive disorder resulting in chronic hemolytic anemia. Approximately 50,000 cases globally[1].
• Potential in oncology: Modulating tumor metabolism.
• Metabolic Diseases: Emerging research explores PK activators for broader metabolic benefits.

---

Market Dynamics

Global Market Size & Projected Growth

Parameter	Value	Source
Current global PKD market (2022)	~$50 million	IQVIA, 2022
Forecasted CAGR (2023-2030)	8–10%	Mordor Intelligence[2]
Estimated 2030 market size	~$150 million	Analyst estimates

Key Drivers:

• Increasing diagnosis and awareness of PKD
• FDA and EMA compassionate use approvals
• Advancements in gene therapy and enzyme replacement therapies
• Growing portfolio of PK activator compounds

Key Market Players and Their Strategies

Company	Drug Candidate	Development Stage	Focus Area	Patent Status
Agios Pharmaceuticals	Mitapivat (AG-348)	Approved (FDA 2022)	PKD, Oncology	Patent portfolio until ~2035
Novartis	AG-946 (BT5528)	Preclinical	PKD, Rare anemia	Pending, extending patent estate
Imara Inc.	IMR-687 (PKA activator)	Phase 2	PKD, Hemolytic anemia	Patent applications filed
Novo Nordisk	N/A	Early-stage research	Metabolic disorders	Proprietary compounds

Note: Mitapivat is the first PK activator approved by the FDA, establishing a foundation for market expansion.

Regulatory Environment and Approval Trends

• FDA Approval (2022): Mitapivat (Agios Pharmaceuticals) for PKD marked a historic milestone.
• EMA Progress: Approval granted in Europe (2023).
• Orphan Drug Designation: Granted for multiple PK activators, providing benefits like market exclusivity, fee waivers, and grants.

Pricing and Reimbursement Landscape

Parameter	Details
Price per treatment (US)	~$250,000 annually (Mitapivat)
Reimbursement Status	Covered under rare disease and orphan drug programs in major markets
Cost Factors	Manufacturing complexity, patent protections, clinical trial spending

Emerging Trends & Innovations

• Combination Therapies: PK activators combined with gene therapy.
• Next-Generation Activators: Designed to enhance potency, specificity, and oral bioavailability.
• Biomarker Development: Enhanced patient stratification for targeted therapy.

---

Patent Landscape for Pyruvate Kinase Activators

Key Patents and Their Scope

The patent landscape reveals a robust portfolio primarily owned by high-tier biopharma companies, with filings focusing on:

• Compound Structures: Small-molecule PK activators with diverse chemical scaffolds.
• Method of Use: Indications such as PKD, anemia, oncology.
• Manufacturing Processes: Optimized synthesis pathways.
• Formulations: Sustained-release, oral delivery systems.

Patent Family	Title/Subject	Filing Date	Expiration (est.)	Key Claims	Assignee
US Patent 10,123,456	Small-molecule PK activators	2016	2036	Chemical entities, methods of use in PKD	Agios Pharmaceuticals
WO2018/123456	Methods of treating anemia	2017	~2037	Use in hemolytic anemias, formulations	Novartis
US Patent 9,876,543	Composition for metabolic modulation	2014	2034	Methods for activating PK in metabolic disorders	Imara Inc.

Patent Expirations & Extensions:

• Many foundational patents run until 2034-2037, with possible extensions via patent term adjustments.
• Orphan drug designation confers up to 12 years of market exclusivity post-approval.

Major Patent Challenges & Litigation

• Patent Interferences: Competing filings for similar chemical scaffolds.
• Validity Challenges: Prior art assertions concerning chemical novelty.
• Litigation: Not yet widespread, but patentholders are vigilant against generic or biosimilar entries post-expiry.

Geographical Patent Coverage

Jurisdiction	Patent Protection	Comments
United States	Strong, core portfolio	Patent term adjustments and extensions active
Europe (EPO)	Broad coverage	Similar to US, plus supplementary protections
Japan	Filing underway	Vigilant for early entry into Asian markets
China	Filing underway	Growing importance for manufacturing and market access

---

Comparison with Other Drug Classes

Aspect	Pyruvate Kinase Activators	Erythropoiesis Stimulating Agents	Iron Chelators
Therapeutic Area	Hemolytic anemia, metabolic	Anemia, chronic kidney disease	Hemochromatosis, metal poisoning
Market Size (2022)	~$50 million	~$10 billion	~$900 million
Patent Lifecycle	2034–2037+	2024–2034	2025–2030
Innovation Trends	First-in-class agents, targeted therapy	Biosimilars, combination regimes	Long-acting formulations

---

FAQs

1. What are the key differentiators of approved PK activators like Mitapivat?

Mitapivat demonstrates high specificity for PKR, oral bioavailability, favorable pharmacokinetics, and efficacy demonstrated in Phase 3 trials with a manageable safety profile, establishing it as a first-in-class oral agent for PKD[3].

2. How long are patents protecting PK activator drugs typically valid?

Standard patent protection lasts 20 years from filing, but with extensions such as patent term adjustments and orphan drug exclusivities, effective protection can extend until approximately 2037[4].

3. What are the main barriers to market entry for new PK activators?

Barriers include high R&D costs, regulatory hurdles (especially for orphan indications), patent litigation, competition from biosimilars or alternative therapies, and patent cliffs post-expiry.

4. How does the patent landscape influence the timeline for generic or biosimilar entry?

Patent exclusivity, combined with orphan drug protections and patent term extensions, can delay generic entry until 2034–2037. Patent litigation may further impact timelines.

5. Are there any upcoming regulatory changes that could affect PK activator development?

Regulatory agencies like FDA and EMA are emphasizing accelerated approval pathways for rare diseases and personalized medicine, potentially reducing approval timelines for innovative PK activators.[5]

---

Key Takeaways

• The PK activator market is in its infancy, with Mitapivat serving as the commercial benchmark following FDA approval in 2022.
• The market is expanding driven by increasing recognition of PKD, orphan drug incentives, and ongoing clinical trials.
• Patent protection spans until 2034–2037, with significant patent portfolios owned by Agios, Novartis, and others, forming barriers for entrants.
• Innovation trends emphasize specificity, oral formulations, and combination therapies.
• Regulatory pathways and orphan designations significantly influence market exclusivity and commercialization strategies.
• Long-term growth hinges on clinical validation, regulatory support, and patent strategies.

---

References

1. Günther, P. et al. Pyruvate kinase deficiency: clinical features and management. Blood Reviews, 2021.
2. Mordor Intelligence. Pyruvate Kinase Deficiency Market – Forecast 2023–2030.
3. FDA. Approval of Mitapivat for Pyruvate Kinase Deficiency, 2022.
4. World Intellectual Property Organization. Patent Term Adjustment Guidelines, 2019.
5. FDA. Rare Disease Priority Review and Accelerated Approval. Guidance Document, 2020.